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                    ABSTRACT 
 
STUDY OBJECTIVE: To study the hs CRP level in acute ischemic stroke and its 
association with short term prognosis. 
DESIGN AND STUDY: Single centered, Prospective study, Thanjavur Medical 
College. 
PATIENTS: 52 patients admitted within 48 hours of onset of first ischemic 
stroke were studied. 
STUDY PERIOD: Between February 2006 and August 2007. 
RESULTS: Following results were obtained, 
1. The hs CRP level is increased in all patients after acute ischemic stroke.  
(Mean hs CRP – 5.94 ± 1.97). 
2. The hs CRP level strongly correlates with short term outcome in patients 
after first ever ischemic stroke. (p < 0.0005) 
3. The hs CRP level is high in patients with massive infarct in CT brain. 
4. The hs CRP level is increased in smokers, obesity, diabetes, hypertension 
and in post menopausal women. 
5. The hs CRP level increases as age advances.  
6. TC/HDL ratio, HDL level (<45mg/dl) strongly correlate with short term 
outcome after acute ischemic stroke. (p < 0.0005) 
7. TC level (>200mg/dl),diabetic status(FBS>125mg/dl), strongly correlate 
with short term out come after acute ischemic stroke.(p=0.022) 
CONCLUSION: Patients with stroke had high circulating levels of hs CRP. Short 
term unfavorable prognosis seems to be associated with elevated hs CRP levels 
in stroke.    
Keywords: stroke, hs-CRP, TC, HDL, Glasgow outcome scale. 
 
 CHAPTER - 1  INTRODUCTION 
 
 
 Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             INTRODUCTION 
 
         Acute ischemic stroke develops as a result of sudden interruption 
in the focal cerebral blood flow31,88.   
 
        The cause of the stroke is an embolic or thrombotic occlusion in 
70-80% of patients with severe symptoms23,87.    
                                                                                              
        Recent research has shown that an inflammatory reaction is 
triggered within the hour in the brain tissue injured by an ischemic 
stroke and continues in the days following the appearance of symptoms 
and that this reaction contributes to neuronal damage13.            
     
       Increased CRP levels are accepted as a sensitive but non specific 
marker of the acute inflammatory conditions50.       
                                                                                      
       Laboratory and experimental findings have shown that 
atherosclerosis is a reflection of a chronic inflammatory process in 
addition to lipid deposition56,70. Inflammatory mechanisms have been 
1 
known to play a role in all stages of atherosclerosis, from initiation to 
development7,52,74,75.  
 
       It has been reported that it is possible to use the increase in the 
concentration of acute phase reactants and especially the high 
sensitivity C- Reactive proteins (hs CRP) to help predict future 
cardiovascular mortality37,52,70,73. Various prospective studies have found 
initial CRP levels to be higher in persons who develop stroke, IHD, 
peripheral artery disease54,60.       
                                                                                                  
   Among all neurological disorder of adult life, CVA clearly rank first 
in frequency and importance posing a major socio economic challenge in 
occupational neuro rehabilitational programmes of stroke survivors.      
                                                                     
Identification of risk factors and its interactions with other 
precursors may yield important clues concerning pathogenesis and 
thereby led to stroke prevention.                   
        Our study was done in Thanjavur Medical College that caters 
population from SIX nearby districts.   
2 
   
CHAPTER - 2  AIM OF THE STUDY 
 
 
 Aim of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim of the study 
 
1. To determine the hs CRP level following acute ischemic 
stroke and its association with short term prognosis.                             
                                                                                                                        
2. To correlate the level of hs CRP with severity of acute 
ischemic stroke.                                  
 
3. To study the relationship of hs CRP level with various known 
risk factors of ischemic stroke. 
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 CHAPTER - 3  REVIEW OF LITERATURE 
 
 
 Definition of Stroke 
 Epidemiology  
 Pathophysiology of Stroke 
 Pathophysiology of Ischemic Stroke 
 Risk Factors 
 Inflammation Endothelial dysfunction and 
Atherogenesis 
 Risk factors and mechanism of injury 
 CRP as a predictor of stroke risk 
 Stroke scales 
 
 
 
  
Review Of Literature 
 
3.1     DEFINITION OF STROKE:      
                Stroke by definition is a syndrome of rapidly developing clinical 
signs of focal disturbance of cerebral function with symptoms lasting 24 hours 
or longer or leading to death with no apparent cause other than vascular 
origin.                                              
3.2     EPIDEMIOLOGY:                                                                                 
       3.2.1     WORLD:                                                     
                Each year stroke affects 15,000,000 people worldwide, two thirds 
of whom die or are left permanently disabled [40]. In 1990 more than 
38,000,000 disability adjusted life years were lost worldwide due to stroke; 
this disease burden is projected to increase to 61,000,000 disability adjusted 
life years by 2020.                                                                              
        3.2.2     INDIA:                                         
                Based on retrospective analyses of subjects admitted in urban 
hospitals in India it was found that stroke constitutes nearly 2% of all hospital 
cases and 20% of neurological admissions.  
                                            
              
4 
3.3   PATHOPHYSIOLOGY OF STROKE:     
                                        
One of the three mechanisms is usual.                                                       
(1) Arterial embolism from distant site usually the carotid, vertebral or 
basilar arteries and subsequent brain infarction.                                                      
(2) Arterial thrombosis causing occlusion in atheromatous carotid, vertebral 
artery with subsequent brain infarction. 
(3) Hemorrhage into the brain (intracerebral or subarachnoid).                                      
                             
 Less commonly,                                                                                                        
• Venous infarction 
• Carotid or vertebral artery dissection 
• Polycythemia 
• Fat and air embolism 
• Multiple sclerosis 
• Mass lesions 
• Very rarely arteritis, neurosyphilis, SLE, and mitochondrial 
disease. 
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3.4    PATHOPHYSIOLOGY OF ISCHEMIC STROKE: 
 
         A fall in cerebral blood flow to zero causes death of brain tissue within 
4-10 min.                                                
       CBF <16 to 18 ml/100gm tissue per min cause infarction within an 
hour. Values <20 ml/100gm tissue per min cause ischemia without infarction 
unless prolonged for several hours or days. There is a loss of neuronal 
electrical function which is reversible stage.   
      
When blood flow decreases to 10 ml/100gm/min then aerobic 
mitochondrial metabolism fails and anaerobic metabolism leads to lactic 
acidosis. As a sequel to this, sodium and water reenter the cell and potassium 
leaks out of the cell due to failure of energy dependant intracellular 
homeostasis leading to irreversible cell death.                                    
     
 Based on these facts, concept of ischemic penumbra was formulated. 
It is an area of brain that has reached the reversible stage of electrical failure, 
but has not yet passed into irreversible stage. Thrombolytic agents are used 
in this time window to salvage the ischemic penumbra zone.              
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3.5     RISK FACTORS:                                        
    NON MODIFIABLE:                                      
• Age  (increases with age) 
• Gender ( males > females ) 
• Hereditary / familial factor 
• Race/ ethnicity. 
   MODIFIABLE RISK FACTORS: (Table 3.1) 
 
 
         RISK FACTOR 
 
 
    INTERVENTION 
REDUCTION IN
ISCHEMIC 
STROKE RISK 
• Hypertension 
• Smoking 
• Lifestyle 
• Alcohol 
• Hypercholesterolemia 
• Raised haematocrit 
• Atrial fibrillation 
• Sleep apnoea 
• Obesity 
• Diabetes 
• Carotid artery stenosis 
• Treat 
• Stop 
• More active 
• Moderate intake 
• Statin therapy 
• Reduce 
• Anticoagulate 
• Treat 
• Wt reduction 
• Good control 
• Surgery 
• + + 
• + + 
• + 
• + 
• + 
• + 
• + 
• + 
• Probable 
• Probable 
• + + 
+ +, Major correlation with reduced risk,  +, moderate correlation with reduced risk. Ref : Clinical Medicine.,Kumar and 
clark.,6th ed., 
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3.6 INFLAMMATION, ENDOTHELIAL DYSFUNCTION      
ATHEROGENESIS:    
 
          Atherogenesis is itself an inflammatory process. When endothelium 
is physically challenged or becomes dysfunction ,  a cascade of events 
precipitated initiating a cycle of injury , immunological induction and 
amplification.  
 
          Causes of endothelial dysfunction include     sheer stress  related to 
hypertension, oxidized LDL , homocysteine, and smoking . Dysfunctional 
endothelium leads to increased permeability to lipoprotein and  
upregulation of  leucocyte and endothelial adhesion molecules.   
 
           In response to the presence of certain activating substances 
including oxidized LDL , monocytic chemoattractant protein (mcp-1) , 
interleukin IL-8 and PDGF leukocytes migrate into the wall of the artery. 
  
          Induced by oxidized LDL , mcp-1 promotes  diapedesis   of 
monocytes across the endothelium . Granulocytic macrophage colony-
stimulating factor transforms monocytes into macrophages, which 
elaborate tumour necrosis factor-ά (TNF-ά) , IL-1 , proteolytic enzymes 
8 
including matrix metalloproteinases and growth factors including PDGF ,  
insulin like growth factor (IGF) .  
 
          These macrophages in addition to smooth muscle , activate T cells 
by presenting antigens including oxidized LDL . Other trophic factors such 
as IL-2 , TNF-ά,  and GM-CSF cause activated Tcells  to produce INF-ά, 
TNF-ά, and TNF-β leading to stimulation of macrophages and further 
upregulation of leukocyte adhesion molecules . This feedback amplifies 
cycle of inflammation.  
 
          Regulation of adhesion molecules also is influenced by mechanical 
forces. Low sheer stress upregulates expression of  vascular cell adhesion 
molecule (VCAM-1) , why increased sheer stress can lead to increased 
gene expression of intercellular adhesion molecule (ICAM-1), VCAM-1, and 
PDGF-β.  ICAM-1, VCAM-1, are members of an immunoglobulin  super 
family whose members have both a transmembrane region and a 
cytoplasmic tail. They are expressed on endothelial cells and bind to 
integrins CD11a/CD18 and VLA-4 respectively.  CD11a/CD18  are found in 
neutrophils monocytes macrophages and lymphocytes while VLA-4 is 
found on Monocytes and lymphocytes.                                                                           
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Fig-3.1 Inflammation and Atherosclerosis 
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Platelets attach to dysfunctional endothelium, macrophages, and 
expose collagen. The activated platelets release granules containing 
cytokines and growth factor, causing conversion of arachidonic acid to 
both thromboxane A2 leading to further platelet aggregation and leukocyte 
, there by amplifying the inflammatory process. Platelets also can be 
activated by PAF ( platelet activating factor ) produced by monocytes, 
endothelial cells and  neutrophils. PAF causes platelet aggregation and 
degranulation and also promote leukocyte activation.  
    To summarize the process of plaque formation initiate with  one or 
more injurious   factors. The resultant inflammatory cascade leads to 
incorporation of oxidized LDL into macrophages forming   foam cells, 
which together with T cells, make fatty streaks. Next PDGF, TGF-β , FGF-2 
act to cause smooth muscle migration to the site .  Next increased activity 
of specific chemokines and cytokines leads to the  formation  of fibrous 
cap on top of necrotic core of lipid , leukocytes and debris. The continued 
presence of macrophages producing metaloproteinases and other 
proteolytic enzymes cause  thinning of fibrous cap and   priming it  for 
ulceration  and rupture.  
      Importantly, the recognition of the importance of the inflammatory 
milieu within atherosclerotic plaque in precipitating plaque erosion and 
11 
rupture leading to events has redirected attention away from the focus 
solely on the degree of stenosis in the arterial tree. Most acute myocardial 
infarctions, for example, occur in patients with substenotic lesions. 
According to the current model of atherosclerosis, initial plaque formation 
is abluminal, or external to the lumen, and is angiographically silent. 
Newer techniques such as intravascular ultrasound (Raggi, 2005) or 
contrast-enhanced carotid MRI86 can detect abnormal and active plaque 
even in the absence of stenosis.            
 Although established as the cause of coronary artery occlusion, and 
as a possible final mechanism of extracranial carotid artery occlusion, this 
ulceration/rupture is not typical of intracranial arterial occlusion38. Although 
atherosclerotic lesions in different vascular beds share many 
characteristics, mechanisms related to symptomatic conversion are likely 
site-specific. Most stroke risk are associated with carotid stenosis. 
          Recent evidence implies that the risk of clinical events is related not 
only to local factors within the atherosclerotic plaque, such as the state of 
the necrotic core or the fibrous cap, but also to blood-borne, or systemic 
factors39. Thus, circulating levels of cytokines, prothrombotic factors or 
acute-phase reactants may play a role in precipitating acute stroke in the 
setting of diseased but not stenotic vessels. For example, evidence exists 
12 
that markers such as CD40 ligand and CRP predict progression of 
atherosclerosis and risk of stroke49. 
3.7     Risk factors and mechanism of injury: 
3.7.1     Hypertension: 
              Hypertension confers a relative risk for stroke of 3- to 5-fold6. It 
continues to represent a significant public health risk. Recently, even high-
normal blood pressures, 130-139/85-89 mm Hg, have been shown to be 
associated with elevated cardiovascular risk84. Hypertension can result in 
mechanical injury to endothelium through increased sheer stress, thereby 
increasing the number of endothelial adhesion molecules, which attract 
monocytes and lymphocytes.                 
        Overactivity of the renin-angiotensin system has been implicated in 
the progression of atherosclerosis. Angiotensin II, in addition to being a 
potent vasoconstrictor, can lead to smooth muscle hypertrophy, 
extracellular matrix production, and induction of cytokines. Expression of 
angiotensin-converting enzyme (ACE) has been demonstrated in 
macrophages, lymphocytes, and microvessels neighboring carotid 
plaques21.  
13 
     This suggests a role for ACE inhibitors as part of a prophylactic 
regimen for stroke. One study showed that patients with vascular disease 
who were treated with the ACE inhibitor ramipril had a lower stroke rate 
than patients treated with placebo82 (Heart Outcomes Prevention 
Evaluation Study investigators). Additionally, a substudy evaluating plaque 
progression using ultrasound suggested that ramipril also may retard 
atherosclerotic progression (Lonn et al, 2001).  
   Independent of the effects of angiotensin II, hypertension has been 
shown in animals to increase formation of hydrogen peroxide and free 
radicals, which in turn can increase leukocyte adhesion74,79. Thus, 
additional pathophysiologic studies are needed.  
3.7.2     Low-density lipoprotein: 
          Oxidized LDL is a relatively active form of LDL, which attracts 
monocytes, increases adherence of monocytes, induces conversion of 
monocytes to macrophages, and decreases the motility of macrophages. 
While native LDL cannot be incorporated into a macrophage or smooth 
muscle cell, oxidized LDL can be taken up by scavenger receptor A (SRA), 
allowing for formation of foam cells. High plasma levels of LDL increase 
14 
the entry rate of LDL into the intima. Serum high-density lipoprotein (HDL) 
exerts a protective effect by deterring LDL peroxidation.  
 
          Macrophages, smooth muscle cells, and endothelial cells can oxidize 
LDL. This leads to a spectrum of variably oxidized LDLs with a 
heterogeneity of deleterious effects. In culture, oxidized LDL is toxic to 
endothelial cells. Studies have shown the presence of oxidized LDL at sites 
of inflammation, raising a potential mechanism by which areas of 
inflammation may promote atherogenesis at remote sites. 
 
           Several studies support a role for beta-hydroxy beta-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (ie, statins) in slowing the 
progression of intima media thickness, a frequently used surrogate for 
carotid atherosclerosis22 (Crouse, 1995). Lowering of LDL has also been 
associated with reduction in plaque progression in studies using 
intravascular ultrasound48. 
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Table 3.2 – Secondary Prevention Trials of Statin Therapy 
          4S        CARE        LIPID 
Duration(yrs) 5.4 5 6.1 
Intervention Simvastatin,  
10-40 mg/day 
Pravastatin, 
40mg/day 
Pravastatin, 
40mg/day 
% LDL change -36 -28 -25 
% change in     
stroke risk 
-30 -31 -19 
 
3.7.3     Diabetes mellitus : 
          Diabetes mellitus (DM) increases stroke risk by 1.5- to 3-fold. Not 
only does DM increase the risk of stroke, it also increases the rate of 
mortality from stroke. DM accelerates atherosclerosis and induces both 
microangiopathic changes and large-vessel atherosclerosis. Long-standing 
DM is associated with endothelial dysfunction, including reduction in 
endothelium-mediated vasodilator production. Additionally, acute 
hyperglycemia has been demonstrated to impair cerebrovascular reactivity 
mediated, at least in part, by endothelial production of nitric oxide and 
prostaglandins10.  
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3.7.4     Smoking : 
           Smoking represents a significant and modifiable risk factor. It 
almost doubles the risk of stroke. This is thought to occur by multiple 
mechanisms. Smoking leads to decreased arterial wall compliance, 
increased platelet aggregation, increased fibrinogen levels, and decreased 
HDL cholesterol levels. 
           A small study recently showed that smokers had lower production 
of endogenous tissue plasminogen activator (tPA) antigen induced by 
substance P infusion, suggesting an impairment of endogenous fibrinolysis 
in smokers (46).Endogenous tPA can be released by endothelial cells to 
lyse subclinical clots, which may exist on denuded areas on the surface of 
atherosclerotic plaques.  
3.7.5     INFECTION : 
        In light of the increasing acceptance of atherosclerosis as a chronic 
inflammatory disease, it has been hypothesized that acute and chronic 
infections may play a role in vascular disease. Increased leukocyte counts 
are associated in observational studies with carotid thickness17 and aortic 
arch plaque thickness19 in some populations as well as with clinical 
stroke18. In a clinical trial in which leukocyte levels were followed 
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repeatedly over time, evidence suggested that those patients who had 
recurrent clinical events were more likely to have had recent elevations in 
their leukocyte counts26. These findings indirectly implicate infection in the 
pathogenesis of plaque formation and stroke risk.  
           Several studies provide evidence that patients with stroke are more 
likely than control subjects to have had an upper respiratory infection 
within the previous 2 weeks25 (Bova, 1996). This suggests a plausible role 
for infection in the conversion of an asymptomatic to a symptomatic 
plaque.  
3.7.6     Chlamydia : 
          C pneumoniae is the infectious pathogen that has been most 
extensively studied in relation to atherosclerosis and stroke. The presence 
of C pneumoniae in the intima, media, macrophages, and smooth muscle 
of some carotid endarterectomy specimens is evident. Detection of C 
pneumoniae in serum, however, correlates poorly with its detection in 
carotid plaques (LaBiche, 2001).  
          Evidence also exists that patients with coronary disease33 and 
stroke18 are significantly more likely than control subjects to have elevated 
levels of immunoglobulin G (IgG) or immunoglobulin A (IgA) against C 
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pneumoniae. However, prospective studies have not always confirmed 
these findings33.  
          In an animal study, inoculation with C pneumoniae increases 
atherosclerosis, and azithromycin attenuates this effect43.                      
Facilitates conversion of macrophages to foam cells; increases the 
oxidation of LDL.  Hypersensitivity to heat stroke proteins also play a role. 
 
3.8 Inflammatory Biomarkers  As  Predictors of Stroke Risk: 
        ♣  Of all inflammatory biomarkers C reactive protein is most 
extensively studied. 
3.8.1     CRP: 
         CRP is an acute phase reactant and a component of innate 
immunity, increases in response to inflammatory stimuli and is a known 
mediator of complement activity, adhesion molecule production, and 
chemokine and thrombogenic factor release.   
          The physiological function of CRP is to induce non specific defense 
mechanism to scavenge altered lipoproteins. 
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           In the past CRP was used only as acute phase protein with cut off 
values between  0.5 and 1.0 mg / dl. 
          Conventional nephelometric and turbidimetric tests allow the 
measurement of concentrations of 0.2 to 0.4 mg/ dl with sufficient 
precision. ELISAs developed for research purposes gave the first indication 
that most healthy persons have a CRP concentration far below these cut 
off values and that higher values are associated with an elevated 
cardiovascular risk59.   
          Later very sensitive commercial tests were developed using mostly 
particle enhanced nephelometry or turbidiometry, where  the sensitivity is 
0.02 mg/ dl. These new tests are called high sensitivity C reactive protein 
(hs CRP ).  
          CRP is produced by liver, vascular smooth muscle cells and 
adipocytes. It is a stable protein not affected by freezing and thawing 
cycles in large epidemiological studies.  It has little diurnal variation and 
can be measured in non fasting state. 
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          The hs CRP, therefore qualifies as a good reproducible assay and 
currently widely available.  
          But CRP is non specific.  Increase in levels occur in acute infections 
and inflammation such as lymphoma, lupus, giant cell arteritis, rheumatoid 
arthritis, inflammatory bowel disease, osteomyelitis. 
3.8.2     CRP – As a Predictor of CVD: 
        Increase in hs CRP levels are independent predictor of risk of 
recurrent myocardial infarction, stroke, peripheral arterial disease and 
sudden cardiac death3,20,66. 
          Studies reveal that highest quartile for CRP compared with the 
lowest quartile was associated with age adjusted relative risk of first 
ischemic stroke and transient ischemic stroke of 2.0 for men and 2.7 for 
women75.  
          CRP adds to the predictive value of  Framingham risk score3 and to 
the vascular risk associated with the metabolic syndrome66. 
           CRP levels showed statistically significant positive correlations with 
other established risk factors including age, number of cigarettes smoked 
per day, body mass index, systolic and diastolic pressure, total cholesterol, 
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triglycerides, homocysteine, fibrinogen and d-dimers. CRP levels correlated 
inversely with HDL – C71. 
           When multi variate analysis was performed to control for these 
associations CRP emerged as a independent risk factor in its own right. 
     Hs CRP was the only inflammatory risk factor that independently 
predicted risk and the inclusion of hs CRP improved the predictive ability of 
the models over those containing lipid values alone ( p < 0.001 ) in several 
studies. (Ridker). 
        The addition of CRP to other CVD risk factors increased the over all 
predictive value. When CRP and TC : HDL ratio were used together, there 
is improvement in risk assessment64. 
         The role of hs CRP and other inflammatory markers has prognostic 
indicators after first stroke has been investigated in many studies15. 
         Hs CRP predicts mortality after stroke14,45. Elevated hs CRP levels in 
patients with stroke is associated with short term unfavorable prognosis80. 
           Patients with the highest CRP quartile experienced reduction in MI 
compared to lowest quartile on aspirin therapy. Helps to identify persons 
who benefit from aspirin therapy.  
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      CRP levels were reduced by lipid lowering drug PRAVASTATIN 
showing that CRP is a modifiable risk factor and suggesting that an anti 
inflammatory activity may contribute to the drugs therapeutic efficacy51. 
 
Table 3.3    Prospective studies of CRP as a Risk Factor for Future Cardiovascular 
Disease: 
Study End point Relative risk*
 
Physician’s Health Study59,60 
 
MI
STROKE 
PVD 
2.9 
1.9 
2.1 
Women’s Health Study62 CVD 4.4 
MRFIT37 CHD Death 4.3 
CHS/RHPP83 CHD 2.3 
MONICA36 CHD 2.7 
Helsinki Heart Study72 CHD 3.6 
* Upper vs Lower Quartile  
 
 
 Table3.4     Reference Values of hs CRP: 
Interpretation CRP (mg/L) 
Low cardiac risk <1.0 
Average cardiac risk 1.0 - 3.0 
High cardiac risk >3.0 
Infection or 
Inflammation 
>10 
 
Table 3.5     Clinical Utility of Novel Markers in CVD Risk: 
 
Marker Assay 
conditions 
standardized?
Prospective 
studies 
consistent?
Additive 
to TC and 
HDL ? 
Additive to 
Framingham 
Risk ? 
 
Lipoprotein(a) - +/- +/- -  
Homocysteine + + +/- -  
tPA & PAI-1 +/- + +/- -  
Hs CRP + + + +  
      
 
 
  
Figure-3.2 : Relative risk of future cardiovascular events 
 
 
Figure-3.3 : CRP level and relative risk of CVD 
 3.9     Stroke Scales: 
                   Some stroke scales used to assess functional outcome are, 
1. Glasgow outcome scale 
2. Barthel index 
3. Modified Rankin scale 
4. NIH Stroke scale 
5. Stroke impact scale 
6. AHA Stroke out come classification 
7. Scandinavian stroke scale 
8. Orgogozo stroke scale 
9. Canadian stroke scale. 
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4     Materials and methods 
4.1     Setting: MEDICAL WARDS, THANJAVUR MEDICAL  COLLEGE.          
4.2     Study design: 
                     This study is single centered prospective study carried out 
in department of medicine of thanjavur medical college during the period 
of February 2006-  August  2007. Total number  of  patients included in 
the study were 52. The detailed history regarding the risk factors like 
diabetes, coronary artery disease, hypertension, hyperlipedemia, smoking, 
and alcohol use were elicited from the patient. Standard approved protocol 
was used for all patients. 
4.2.1     Inclusion criteria: 
1. Age 41-85. 
2. First  acute ischemic stroke were included 
3. Only  ischemic stroke patients confirmed by CT brain were 
included. 
4. Patients  who got admitted within 48 hrs of stroke onset were 
included. 
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4.2.2     Exclusion criteria:  
1. Other than ischemic stroke were excluded.  
2. Patients admitted after 48 hrs of stroke onset were excluded. 
3. Age less than 40 yrs and greater than 85 were excluded. 
4. Patients with lymphoma, lupus, rheumatoid arthritis , 
osteomyelitis, malignancy, other connective tissue diseases 
were excluded. 
5. Recent infection , trauma or surgery within a month were 
excluded. 
6. Patients with   valvular heart disease, atrial fibrillation, 
thyroid disease, renal disturbance were excluded.  
7. Patients with previous history of stroke , TIA , RIND were 
excluded.  
8. Acute myocardial infarction were excluded. 
4.3     Study Method: 
4.3.1     Clinical Examination: 
         All patients were examined for hypertension, obesity, carotid artery 
thrill and bruit. A detailed cardiovascular and CNS examination were 
performed and the findings were recorded. ECG and  Chest X Ray PA view 
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were taken to rule out AF and valvular heart disease as well as acute MI. 
BP  at the time of admission were recorded and BMI were calculated .  
Patients with BMI>30 were labeled as obese.  
4.3.2     Investigations: 
1. Hb%.  
2. Total count, differential count. 
3. Random blood sugar,  urea , creatinine. 
4. Fasting total cholesterol(TC), Fasting high density lipoprotein 
cholesterol(HDL-C). 
5. CT brain plain at the time of admission. 
6. Hs CRP  test was done within 24-48 hours of stroke onset. 
4.4     Hs-CRP test: 
               Specimen: serum or heparinised or EDTA plasma. 
               Volume: 0.5 – 1.0 ml. 
               Storage:  Refrigerate  for maximum 8 days. May be frozen at -
25˚C  or lower if samples are frozen within 24 hrs after collection. 
Repeated freeze thaw cycles to be avoided. 
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                   Method: Nephelometric method utilizing latex particles coated 
with CRP monoclonal antibodies. 
4.4.1      Principle of nephelometry: 
        When light is passed through a turbid solution, light rays strike the 
particles in the solution and change their direction of movement. This 
phenomenon is called scattering. Size, concentration, and shape of 
molecules altogether determine the amount of scattered light. Size and 
shape determines the angle of scatter and concentration intensifies the 
scattered light at the particular angle. The liquid sample is exposed to the 
beam of light rays in a transparent holder. The rays get scattered and a 
detector kept at right angle of the light path detects the intensity of the 
rays at that angle. This is further quantified by rehearsing the phenomena 
with known molecule at known concentration that is using a standard. 
Polystyrene particles coated with the antibodies are agglutinated when 
mixed with the samples containing the test parameter.  
4.4.2     Instrument: BN-100  FROM  DADE BEHRING , USA.        
ADVANTAGES:   
1. Fully automatic and rapid quantititative determination. 
2. Fast with kinetic method. Results in few minutes. 
3. Can perform 100 tests per hour. 
4. Sensitivity- 0.1 mg/l. 
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4.5     Assessing Functional Outcome:  
          ♣    On seventh day patients clinical and functional status were 
assessed  using  GLASGOW OUTCOME SCALE. 
GlasgowOutcomeScale:  
Note: The scale presented here is based on the original article by 
Jennett and Bond.  
SCORE DESCRIPTION 
1 Death 
2 Persistent vegetative state 
Patient exhibits no obvious cortical function. 
3 Severe Disability 
(Conscious but disabled). Patient depends upon others 
for daily support due to mental or physical disability or 
both 
4 Moderate Disability 
(Disabled but independent). Patient is independent as 
far as daily life is concerned. The disabilities found 
include varying degrees of dysphasia, hemiparesis, or 
ataxia, as well as intellectual and memory deficits and 
personality changes. 
5 Good Recovery 
Resumption of normal activities even though there may 
be minor neurological or psychological deficits. 
References 
Jennett B, Bond M. “Assessment of outcome after severe brain damage.” 
Lancet 1975 Mar 1;1(7905):480-4 
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 CHAPTER - 5  RESULTS AND 
OBSERVATIONS 
 
 
 Study results and observations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Results and observation 
5.1     Age: 
                  Patients of age > 40 yrs and < 85 yrs were included in this 
study. 
• Total no of patients – 52 
• Mean age of patients – 60.3 yrs 
• Standard deviation – 10.5 yrs  
• Range – 37 
• Maximum age – 80 yrs 
• Minimum age – 43 yrs 
5.2     Frequency tables: 
Table 5.1 : Sex 
SEX
39 75.0 75.0 75.0
13 25.0 25.0 100.0
52 100.0 100.0
MALE
FEMALE
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• 75 % of patients were males. 
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Table 5.2 : Smoking 
SMOKING
30 57.7 57.7 57.7
22 42.3 42.3 100.0
52 100.0 100.0
YES
NO
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• 57.7 % of this study group were smokers who smokes more than 
one packet per day 
Table 5.3 : Alcohol 
ALCOHOL
8 15.4 15.4 15.4
44 84.6 84.6 100.0
52 100.0 100.0
YES
NO
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• Those who take more than three drinks per day were included. 
• 15% of patients were alcoholics. 
Table 5.4 : Diabetes mellitus 
D.M.
12 23.1 23.1 23.1
40 76.9 76.9 100.0
52 100.0 100.0
YES
NO
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• All patients who were on regular or irregular treatment included. 
• 23% were diabetics in this study. 
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Table 5.5 : Hypertension 
H.T
30 57.7 57.7 57.7
22 42.3 42.3 100.0
52 100.0 100.0
YES
NO
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• Patients who had BP> 140/90 at the time of admission were 
included. 
• 57.7% found to have high BP. 
Table 5.6 : CAHD 
CAHD
4 7.7 7.7 7.7
48 92.3 92.3 100.0
52 100.0 100.0
YES
NO
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• Only 8% had previous history of CAHD. 
Table 5.7 : Obesity 
OBESITY
5 9.6 9.6 9.6
47 90.4 90.4 100.0
52 100.0 100.0
YES
NO
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• Only 10% were obese in this study. 
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Table 5.8 : Total Cholesterol 
 
TCL REC
37 71.2 71.2 71.2
15 28.8 28.8 100.0
52 100.0 100.0
< 200
> 200
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• 71% patients had TC<200 mg/dl. 
• Mean TC 189.6 ± 16.9 ; Median TC 190 ; Range 60  
Table 5.9 : High Density Lipoprotein 
HDLREC
11 21.2 21.2 21.2
41 78.8 78.8 100.0
52 100.0 100.0
> 45
<45
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
• In this study only 22% had  HDL >45mg/dl. 
• Mean HDL 41.08 ± 3.07 ; Median HDL 41 ; Range 11  
Table 5.10 : TC/HDL Ratio 
             
• Ideally it should be less than 4. 
• Mean TC/HDL 4.64 ± 0.6 ; Median TC/HDL 4.64 ; Range 2.3 
• In this study only 17 % had TC/HDL < 4 
TCL /HDL RATIO
9 17.3 17.3 17.3
43 82.7 82.7 100.0
52 100.0 100.0
< 4
>4
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
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Table 5.11 : CRP Distribution 
                 
• Mean hs CRP of all patients 5.94 ± 1.97 ; Median 6.15 ; Range 8.0 
• Maximum value – 10.1mg/l ; Minimum – 2.1mg/l 
   
CRPRECOD
CRPRECOD
10-119-108-97-86-75-64-53-42-3
Fr
eq
ue
nc
y
14
12
10
8
6
4
2
0
 
                        Figure 5.1 : CRP Distribution 
 
• It shows  >94 % of patients had hs CRP > 3mg/l 
• It shows clearly that hs CRP levels are increased in stroke 
CRP DISTRIBUTION 
5 9.6 9.6 9.6
5 9.6 9.6 19.2
7 13.5 13.5 32.7
7 13.5 13.5 46.2
13 25.0 25.0 71.2
7 13.5 13.5 84.6
4 7.7 7.7 92.3
3 5.8 5.8 98.1
1 1.9 1.9 100.0
52 100.0 100.0
2-3
3-4
4-5
5-6
6-7
7-8
8-9
9-10
10-11
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
36 
 
Table 5.12 : Glasgow Outcome Scale 
 
• 70 % had poor prognosis 
• 7.7 % mortality was noted in these patients 
• Only 30 % had good recovery 
GLASGOW SCALE REC
GLASGOW SCALE REC
MILD/ GOODVEG / SEVERE DISDEATH
Fr
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nc
y
40
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0
 
                    Figure 5.2 : Glasgow Outcome Scale 
• Patients with score of 2 and 3 were unable to walk 
• Patients with score of 4 and 5 were able to walk 
 
GLASGOW SCALE REC
4 7.7 7.7 7.7
32 61.5 61.5 69.2
16 30.8 30.8 100.0
52 100.0 100.0
DEATH
VEG / SEVERE DIS
MILD/ GOOD
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
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5.3 RISK FACTOR COMPARISON WITH GLASGOW OUTCOME 
SCALE : 
5.3.1     Hs CRP level and functional outcome : 
Table 5.13 : GLASGOW SCALE REC * CRPRECOD 
 
Crosstab
Count
1 2 1 4
3 4 13 7 4 1 32
5 5 4 2 16
5 5 7 7 13 7 4 3 1 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11
CRPRECOD
Total
 
 
P < 0.0005 (Statistically significant)  
 
 
• Mean hs CRP of all 52 patients 5.94 ± 1.96mg/l  
• Mean hs CRP of all patients who died during study 8.85 ± 1.98mg/l 
• Mean hs CRP of all patients who were unable to walk ( patients in 
GOS score of 2 and 3 ) is 6.68 ± 1.1mg/l 
• Mean hs CRP of patients who were able to walk ( patients in GOS 
score of 4 and 5 ) is 3.73 ± 1.1mg/l 
• Total no of patients who had massive infarct in CT Brain – 9 
• Mean hs CRP who had massive infarct is 8.7 ± 0.96mg/l 
• Total no of patients who had lacunar infarct – 10 
• Mean hs CRP of patients who had lacunar infarct is 3.27 ± 0.93mg/l 
• Applying chi square test for association between hs CRP levels and 
GOS, p < 0.0005 which is statistically significant 
• All these data clearly showed high hs CRP levels following acute 
ischemic stroke indicates poor outcome. 
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Figure 5.3 : GLASGOW SCALE REC * CRPRECOD 
 
• Above graph shows when hs CRP increases, worse is the prognosis. 
 
 
5.3.2     Total cholesterol and functional  outcome:              
 
Table 5.14 : GLASGOW SCALE REC * TCL REC 
Crosstab
Count
1 3 4
21 11 32
15 1 16
37 15 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
< 200 > 200
TCL REC
Total
 
P = 0.014 ( Statistically significant) 
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                             Figure 5.4 : Glasgow Scale REC*TC 
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Figure 5.5 : Glasgow Scale REC*TC(Graph) 
 
• 75 % of patients who died had TC > 200mg/dl 
• 34 % of patients who were unable to walk had TC > 200mg/dl 
• Only 6 % of patients who were able to walk had TC > 200mg/dl. 
• Applying chi square test p ═ 0.014 statistically significant 
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5.3.3     HDL and  functional outcome : 
 
Table 5.15 : GLASGOW SCALE REC * HDLREC 
 
Crosstab
Count
1 3 4
1 31 32
9 7 16
11 41 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
> 45 <45
HDLREC
Total
 
P < 0.0005 ( Statistically significant )  
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                   Figure 5.6 : Glasgow Scale REC* HDL REC 
 
• 56 % of patients who were able to walk had HDL > 45mg/dl 
• Only 3 % of patients who were unable to walk had HDL > 45mg/dl. 
• Applying chi square test p < 0.0005 statistically significant. 
• This shows patients who had HDL > 45mg/dl had good outcome. 
 
 
 
5.3.4     TC/HDL and functional outcome : 
 
Table 5.16 : GLASGOW SCALE REC * TCL / HDL RATIO REC 
 
Crosstab
Count
4 4
1 31 32
8 8 16
9 43 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
< 4 >4
TCL / HDL RATIO REC
Total
 
P < 0.0005 (Statistically significant)  
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               Figure 5.7 : GLASGOW SCALE REC * TCL / HDL RATIO REC 
 
• All the patients who died had TC/HDL > 4. 
• 96 % of patients who were unable to walk had TC/HDL > 4. 
• Only 50 % of patients who were able to walk had TC/HDL > 4 . 
• Applying chi square test p < 0.0005 statistically significant. 
• More the TC/HDL, worse the outcome. 
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         Figure 5.8 : GLASGOW SCALE REC * TCL / HDL RATIO REC(Graph) 
 
• As TC/HDL ratio increases, worse is the outcome 
 
5.3.5 Smoking and functional outcome:  
 
 Table 5.17 : GLASGOW SCALE  AND  SMOKING   COMPARISION 
Crosstab
Count
3 1 4
15 17 32
12 4 16
30 22 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
YES NO
SMOKING
Total
 
 
   p > 0.05 ( NOT SIGNIFICANT)   
 
• Applying chisquare  p>0.05, stastistically not significant. 
• 75% of patients who died were smokers. 
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 5.3.6      Alcohol and functional outcome: 
 
Table 5.18 : GLASGOW SCALE REC * ALCOHOL COMPARISION 
Crosstab
Count
4 4
6 26 32
2 14 16
8 44 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
YES NO
ALCOHOL
Total
 
   p > 0.05 ( NOT SIGNIFICANT)   
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                        Figure 5.9 : GLASGOW SCALE REC * ALCOHOL COMPARISION 
 
Alcohol not associated with short term outcome in this study. 
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5.3.7     HT and functional outcome: 
 
Table 5.19 : GLASGOW SCALE REC * H.T 
 
Crosstab
Count
4 4
20 12 32
6 10 16
30 22 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
YES NO
H.T
Total
 
p > 0.05 ( NOT SIGNIFICANT)   
  
• Hypertension not associated with short term outcome in this study. 
 
 
5.3.8     CAHD and functional outcome: 
 
Table 5.20 : GLASGOW SCALE REC * CAHD 
 
Crosstab
Count
1 3 4
3 29 32
16 16
4 48 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
YES NO
CAHD
Total
 
 
p > 0.05 ( NOT SIGNIFICANT)   
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                                  Figure 5.10 : GLASGOW SCALE REC * CAHD 
 
 
 
5.3.9 Obesity and functional outcome: 
 
Table 5.21 : GLASGOW SCALE REC * OBESITY 
Crosstab
Count
1 3 4
4 28 32
16 16
5 47 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
YES NO
OBESITY
Total
 
 
 
p > 0.05 ( NOT SIGNIFICANT)  
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5.3.10     DM and functional outcome: 
 
Table 5.22 : GLASGOW SCALE REC * D.M. COMPARISION 
 
Crosstab
Count
2 2 4
10 22 32
16 16
12 40 52
DEATH
VEG / SEVERE DIS
MILD/ GOOD
GLASGOW
SCALE REC
Total
YES NO
D.M.
Total
 
  P = 0.022 ( Statistically significant)    
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               Figure 5.11 : GLASGOW SCALE REC * D.M. COMPARISION 
 
• 50% Patients died were alcoholic . 
• Applying chi square test p<0.022, statistically significant. 
• So diabetes influences outcome in stroke patients. 
 
 
In this study outcome is strongly determined by hs-CRP levels, HDL, TC, TC/HDL levels, and 
also diabetic status. 
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5.4     Comparison of Hs CRP with other Known risk factors : 
   5.4.1      Hs CRP with age:  
                Mean hs-CRP of all patients: 5.94mg/l. 
                  No of pts in age group 40-50: 10 
                  Mean hs-CRP of pts in age group 40-50: 4.72 mg/l. 
                  No of pts in age group 50-60: 22 
                  Mean hs-CRP of pts in age group 50-60: 5.7 mg/l. 
                   No of pts in age group 60-70: 11 
                  Mean hs-CRP of pts in age group 60-70: 6.56mg/l 
                  No of pts in age group 70-80: 4. 
                  Mean hs-CRP of pts in age group 70-80: 7.12mg/l.  
 
5.4.2     Hs CRP with GENDER: 
                   Mean hs-CRP of all patients: 5.94mg/l. 
                  Mean hs- CRP of men: 5.65mg/l. 
                  Mean hs- CRP of women: 6.38mg/l.   
                  ( all are post menopausal) 
          
5.4.3     Hs CRP with SMOKING:  
                   Mean hs- CRP of men: 5.65mg/l. 
                  Mean hs- CRP of men who were smokers: 5.85mg/l. 
                  Mean hs- CRP of men who were non smokers: 5.0 mg/l 
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5.4.4     Hs CRP with DM:  
                Mean hs- CRP of  pts  who were diabetic: 7.73mg/l. 
                  Mean hs- CRP of pts who were non-diabetic: 5.4 mg/l. 
 
5.4.5     Hs CRP with HT: 
                   Mean hs- CRP of  pts  who were hypertensive: 6.65mg/l. 
                  Mean hs- CRP of  pts  who were not  hypertensive: 4.98mg/l. 
 
5.4.6     Hs CRP with CAHD: 
                  Mean hs- CRP of   pts   with   h/o CAHD: 8.45mg/l. 
                  Mean hs- CRP of   pts   without   h/o CAHD: 5.73mg/l. 
 
5.4.7     Hs CRP with OBESITY: 
                  Mean   hs- CRP of   pts   with  BMI>30: 8.18mg/l. 
                  Mean   hs- CRP of   pts   with  BMI<30: 5.72 mg/l. 
 
5.4.8      Hs CRP with alcohol:  
                Mean   hs- CRP of   pts   who were alcoholic: 6.79mg/l. 
                  Mean   hs- CRP of   pts   who were  non-alcoholic: 5.79mg/l. 
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           DISCUSSION 
 
           Total no of patients in this study was 52. Hs CRP estimate was 
done on all patients on the second day after the onset of stroke ie, within 
24 to 48 hrs after onset of stroke. 
          Various known risk factors of stroke like age, sex, diabetes, 
hypertension, smoking, alcohol, total cholesterol level, HDL level, TC/HDL 
ratio were compared with hs CRP level. Functional outcome after stroke is 
analysed with hs CRP level and other risk factors. 
 
6.1     AGE: 
 
           Of the 52 patients, 10 were in the age group of 40 to 50 yrs, and 
22 were in age group of 50 to 60 yrs, 11 were in 60 to 70 yrs and 4 
patients were in age group of 70 to 80 yrs. 
 
          The mean hs CRP level in each group in ascending order were 
4.72mg/l, 5.7mg/l, 6.56mg/l and 7.12mg/l. Thus a gradual increase in hs 
CRP with age was noted.  
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            This correlates with study by M.A.Mendal et al41, Praful patel et al, 
that there is an elevation in hs CRP as age advances. Another study by Seishi 
yamada et al77 in Japanese population also confirmed this observation. In the 
study by Nakogmi et al1 that in elderly patients there is increase in hs CRP 
level which in turn increase the production of tissue factor by monocytes. The 
monocyte tissue factor production is increased by several folds in elderly 
patients. This tissue factor is responsible for activation of extrinsic coagulation 
cascade leading to thrombus formation and cardiovascular events in elderly 
population. 
 
6.2      GENDER: 
 
        In this study 39 were male (75 %) and 13 were female   (25 %). 
The mean hs CRP level in male was 5.65mg/l and female was 6.38mg/l. 
 
          In a study by Nakagomi et al1 showed that as age advances the hs 
CRP level gradually rises. The hs CRP levels of women of post menopausal 
age were significantly greater than values in men of similar age group. 
Since all the female patients in this study were postmenopausal the mean 
hs CRP of females was greater than males.  
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 6.3     SMOKING: 
 
        There were 39 men in this study, out of them 30 were smokers who 
used to smoke greater than 10 cigarettes per day for several years. 
 
          Mean hs CRP of the men who smokes was 5.85mg/l and non 
smokers was 5mg/l. 
 
          In a study by Haverkate et al, the elevation of CRP level in smokers 
is about 50% more than that of non smokers. Study by 
Timo.E.Strandberg81 confirmed hs CRP elevation in smokers. 
 
          The main mechanism for this elevation may be the increase in 
inflammation in vessel wall which causes CRP elevation and there by 
increase in atherosclerosis progression. 
 
          In this study there is no strong relationship between smoking and 
short term prognosis. No study was done previously to find out association 
between smoking and short term prognosis after stroke. 
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 6.4     ALCOHOL: 
          Only 8 patients in this study were found to be alcoholic. Mean hs 
CRP of these  patients who were alcoholic and non alcoholic were 6.79mg/l 
and 5.79mg/l. No study correlates alcohol with hs CRP level.  
          In this study there is no strong relationship between alcohol intake and 
short term prognosis. There is no study comparing alcohol with short term 
prognosis after acute ischemic stroke. 
 
6.5     HYPERTENSION: 
        ♣    HYPERTENSION AND CRP LEVELS: 
        In this study 30 patients were found to have BP > 140/90 mm Hg at 
the time of admission. Mean hs CRP level in patients who were 
hypertensive was 6.65mg/l, whereas the mean hs CRP in non 
hypertensives was 4.98mg/l. 
 
          In a study by Mario Di Napoli et al14, Franscesca Papa et al# and 
studies by Bautia.L.E, et al, Lopez-Jarmillo et al# and studies by Abramson, 
Weintrub WS et al#, all showed that there is persistent strong significant 
association between hs CRP levels and BP. Even high normal BP 130 – 
139/ 85 – 89 mm Hg is found to increase CRP levels. 
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   ♣   HYPERTENSION AND SHORT TERM OUTCOME: 
          In this study all the dying patients were found to have high BP, and 63 
% of patients who were not able to walk at the end of first week were 
hypertensive but only 38 % of patients who were able to walk at the end of 
first week were hypertensive. Though on applying chi square test p value > 
0.05 which is not statistically significant. 
 
          In the above mentioned studies there is positive correlation 
between hypertension and long term outcome after stroke, but there is no 
study that compares hypertension with short term outcome after acute 
ischemic stroke. 
 
          In a study by Benson and Sacco6, HT confirms relative risk of 3 to 5 
fold. HT can result in mechanical injury to endothelium through increased 
sheer stress, thereby increasing the number of adhesion molecule that attract 
monocytes and lymphocytes. 
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6.6      DIABETES: 
 
      ♣    DIABETES AND HS CRP LEVELS: 
          In this study 12 patients were found to be diabetic. Mean hs CRP of 
diabetic patients were 7.7mg/l compared to 5.4mg/l in non diabetics.  
          In a study by Yudkin et al32, the elevation of CRP levels in healthy 
subjects correlates with insulin resistance and endothelial dysfunction. Many 
studies by Festa.A et al and Leinmoner et al# support this. Also study by 
Manisha Chadalia et al# showed that hs CRP concentration in asian Indian 
living in United States were prone to CVD risk and Diabetes risk. 
 
      ♣     DIABETES AND SHORT TERM OUTCOME: 
              50 % of dying patients were diabetic and no diabetic was 
noted in patients who were able to walk at the end of first week.  
          Applying chi square test p value is 0.022 which is 
statistically significant. Previous studies showed that DM increases 
the risk of stroke and increases the mortality from stroke. Long 
standing DM is associated with endothelial dysfunction which 
promotes inflammation10.DM may be classified as a stroke risk 
equivalent and may warrant more aggressive treatment strategies in 
the future prevention of stroke (Hopaultre,Mose 2003#). 
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 6.7     CAHD : 
 
           ♣  CAHD AND HS CRP LEVEL:  
 
        In this study of 52 patients, only 4 had previous history of CAHD. Of 
all the 4 patients one died during the study and the other 3 are with 
severe disability / vegetative state. 
          Mean hs CRP of patients with previous history of CAHD is 8.45mg/l. 
Mean hs CRP of patients without previous history of CAHD is 5.73mg/l. 
 
            ♣   CAHD AND FUNCTIONAL OUTCOME: 
 
          On applying chi square test p value is > than 0.05 statistically not 
significant. Studies by Kerstein Weinbeck et al34, has found out CRP levels 
after 12 hours of any cardiovascular event predicts the outcome and risk of 
recurrent events. 
6.8     OBESITY: 
         ♣    OBESITY AND HS CRP LEVELS: 
 
         Mean hs CRP of patients who have BMI > 30 in our study were 
8.18mg/l, where as mean hs CRP of patients who have BMI < 30 
were 5.72mg/l. In this study only 5 were found to be obese. 
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          This study strongly correlates with previous study by Yudkin et 
al32 that hs CRP elevation in obesity is due to release of IL-6 from 
adipose tissue that stimulate the hepatic production of CRP leading to 
increased CRP levels. Similar study by Haverkate et al# confirmed this 
observation. 
 
           ♣    OBESITY AND FUNCTIONAL  OUTCOME: 
 
Though studies support obesity with long term poor outcome after 
stroke there is no study to find out association between obesity and short 
term outcome after stroke. In this study on applying chi square test to find 
out association between obesity and short term outcome p value > 0.05 
statistically not significant. 
 
6.9     TOTAL CHOLESTEROL AND FUNCTIONAL   OUTCOME: 
           In this study 37 patients had total cholesterol < 200mg/dl. 75 % of 
people who died during study had a TC > 200mg/dl. 34 % of people who 
were unable to walk after one week had TC > 200mg/dl. Only 6 % of 
patients who were able to walk after one week had a TC > 200mg/dl. 
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          On applying chi square test to find out association between TC and 
short term outcome after stroke, p value is 0.014 which is statistically 
significant. This was supported by many studies. 
          “Benzafibrate” prevention by Nirokiren Morag et al and Sacco et al47, 
showed that patients with high TC had poor outcome. 
 
6.10     HDL LEVEL AND FUNCTIONAL OUTCOME: 
          In this study only 11 patients had HDL level > 45mg/dl and 41 
patients had HDL level < 45mg/dl.  
          56 % of patients who were able to walk at the end of first week 
had HDL > 45mg/dl but only 25 % of patients who died during study had 
HDL > 45mg/dl. Only 3 % of patients who were unable to walk at the end 
of first week had HDL > 45mg/dl. 
          On applying chi square test p < 0.0005, which is highly significant. 
Patients who had HDL > 45mg/dl had better outcome. This was supported 
by many studies.  “Benzafibrate” prevention by Nirokiren Morag et al and 
Sacco et al47, showed that patients with low HDL had poor outcome.  
          In the study by Russel P. Tracy Rozenn, N.Lemaitre et al83., the levels 
of hs CRP correlated proportionately with LDL level and inversely with HDL 
level. This proves the role of inflammation on LDL – C for the progression of 
atherosclerosis. 
58 
 6.11     TC / HDL RATIO AND FUNCTIONAL OUTCOME 
 
In this study totally 43 patients had TC/HDL > 4, all the dying 
patients had TC/HDL >4. 96 % of patients with Glasgow outcome scale 
score of 2 & 3 had TC/HDL > 4. Only 50 % of patients with GOS score of 4 
& 5 had TC/HDL > 4.  
 
   On applying chi square test to find out association between TC/HDL 
ratio with GOS score, p value is < 0.0005, which is statistically significant. 
Studies by Bruce Kinosian et al#, showed that TC/HDL is a superior measure 
of cardiovascular disease compared with either with TC or LDL-C.  
 
          The addition of CRP to other CVD risk factors increased the over all 
predictive value. In particular when hs CRP & TC/HDL ratio were used 
together a significant improvement in risk assessment was achieved 
compared to use of each separately (Ridiker). 
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6.12     Hs CRP LEVEL  AND FUNCTIONALOUTCOME: 
 
In this study of 52 patients the mean hs CRP of all patients done 
on 2nd day after onset of stroke was 5.94 ± 1.96 mg/l. 
Mean hs CRP of patients who had death as end point was 8.85 ± 
1.98 mg/l.  
  Mean hs CRP of patients who had Glasgow outcome scale score of 2 
& 3 ( patients unable to walk ) at the end of 1st week was 6.68 ± 1.1 mg/l.  
 
  Mean hs CRP of patients who had Glasgow outcome scale score of 4 
& 5 ( patients able to walk ) at the end of 1st week was 3.73 ± 1.1 mg/l. 
Mean hs CRP of patients who had massive infarct in CT Brain was 
8.7 ± 0.96 mg/l, whereas mean hs CRP of patients who had lacunar infarct 
was 3.27 ± 0.93 mg/l.  
 
  All these datas clearly show that hs CRP  is increased after stroke 
and the patients who had poor outcome at the end of 1st week after stroke 
had very high levels of hs CRP 
    When we apply chi square test for association between hs CRP 
levels and Glasgow outcome scale for our patients   p value is < 0.0005, 
which is statistically significant. 
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Studies by Tahir Yoldas et al80 ( mediators of inflammation 2007 ), 
clearly showed that levels of hs CRP done on 2nd day after the ischemic 
stroke strongly associated with short term unfavorable prognosis. The 
study also showed that patients with stroke have a higher circulating 
serum hs CRP and Homocysteine levels.  
         Studies by Kerstein Weinbeck et al34  (stroke 2002) also gave similar 
results. Beamer et al# have reported that stroke patients without infections 
have increased levels of CRP.  
         Experimental studies have shown that secretion of inflammatory 
mediators as a direct response to cerebral injury starts within 2 hours of 
focal ischemia and anti inflammatory treatment have neuroprotective role.  
       Muir et al44, have shown CRP levels within 1st 72 hours following an 
acute ischemic stroke as an independent predictor for predicting survival.  
 
Studies by Di Napoli14 has shown that a large infarct and cortical 
involvement in patients had a highest CRP values than normal at the time 
of presentation. This study also confirmed that prognosis in patients with 
increased CRP level is worse. 
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         Our findings that patients who were able to walk had lower hs CRP 
levels than the patients who were unable to walk, and also the patients 
who had death as end point, may be an indicator of the degree of 
inflammation. 
 
     CARE Trial, PROVE-IT-TIMI51 ( PROVASTATIN or ATORVASTATIN 
evaluation and infection therapy – thrombolysis in myocardial infarction ), 
and REVERSAL ( Reversing atherosclerosis with aggressive lipid lowering 
trials ), showed that STATINS significantly reduce mortality and recurrent 
events in patients with high hs CRP levels even when LDL levels are < 130 
mg/dl.                        
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                      CHAPTER – 7  SUMMARY & CONCLUSION 
 
 
  Conclusion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Summary and conclusion 
                            
1. The hs CRP level is increased in all patients after acute ischemic 
stroke. 
2. The hs CRP level strongly correlates with short term outcome in 
patients after first ever ischemic stroke. (p < 0.0005) 
3. The hs CRP level is high in patients with massive infarct thus 
reflecting the severity of stroke. 
4. The hs CRP level is increased in smokers, obesity, diabetes, 
hypertension and post menopausal women. 
5. The hs CRP level increases as age advances. 
6. TC/HDL ratio,HDL level (<45mg/dl) strongly correlate with short 
term outcome after acute ischemic stroke. (p < 0.0005) 
7. TC level (>200mg/dl),diabetic status(FBS>125mg/dl), strongly 
correlate with short term out come after acute ischemic 
stroke.(p=0.022) 
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 APPENDIX 
 
 
 A: Proforma  
 B: Master chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
Name:                                     Age:         yrs                Sex: M/F 
 
IP No:                                   Ward:                            Unit:              
 
 
Presenting Complaints: 
 
Weakness              Loss of consciousness               Facial Weakness   
 
Speech disturbance        Others   
 
 
Risk Factors: 
 
Diabetes Mellitus               Hypertension                               CAHD   
 
Smoking         Alcohol                 Hyperlipidemia   Obesity   
 
 
Clinical Examination: 
 
CNS:               Conscious:                yes/no 
 
                    Orientation:                 yes/no 
 
                          Speech:                Normal/Aphasia/Dysphasia 
 
            UMN Facial Palsy:                 yes/no 
 
                Motor System:                 Hemiplegia/Hemiparesis/Monoplegia/                                  
                                                      Monoparesis/Others 
 
                          Others: 
 
CVS: 
 
RS: 
 
ABDOMEN: 
 
BMI:          >30  <30 
 
Investigations: 
 
URINE:  
 
          Albumin:                   Sugar:                     Deposit:  
 
 
COMPLETE HEMOGRAM: 
 
          Hb:           TC:                  DC:  P     % L     % E     % B     %  M    % 
          RBC:          
          Platelets: 
   
        
BIOCHEMICAL ANALYSIS: 
 
          Blood Sugar: 
          Blood Urea: 
          Serum Creatinine: 
          Serum Electrolytes:                Na+                        K+            
 
 
LIPID PROFILE: 
 
          Total Cholesterol: 
          HDL: 
          TC/HDL Ratio: 
 
ECG: 
 
 
High sensitivity CRP: 
( on 2nd day of stroke ) 
 
 
CT BRAIN: 
 
 
 
FUNCTIONAL OUTCOME: 
( on 7th day of stroke ) 
 
          Glasgow outcome scale score:   1 / 2 / 3 / 4 / 5 
MASTER CHART 
S.No. Name 
A 
G 
E 
S 
E 
X 
IP.No 
RISK FACTORS INVESTIGATIONS 
On 
2nd  
Day  
At  
Discharge 
S
m
o
k
i
n
g
 
A
l
c
o
h
o
l
 
DM HT IHD
O
B
E
S
I
T
Y
 
 
Blood 
sugar 
mg 
TC 
Mg 
% 
HDL 
Mg 
% 
 TC 
/ 
HD 
L  
CT Brain Plain 
 HS 
CRP 
Mg / L 
Glasgow 
Outcome 
Scale 
(Score) 
1 Pappathi 55 F 941880 - - - + - - 98 196 44  4.45 (R) MCA Infarct 
       
6.8  3 
2 Maideen Beevi 45 F 942712 - - + + - + 226 208 41  5.07 (L) MCA Infarct 
       
7.0  3 
3 Saudambal 70 M 922704 - - - + - - 101 190 45  4.22 (L) MCA Infarct 
       
7.1  3 
4 Karunanidhi 60 M 929370 + + - + + - 88 201 36  5.59 
(L) Hemispherical  
Massive Infarct 
       
9.1  2 
5 Jeganathan 80 M 929921 - - - + - - 92 184 36  5.10 (L) MCA Infarct 
       
6.9  3 
6 Samson 45 M 930175 + - - + - - 84 190 45  4.22 (R) MCA Infarct 
       
3.1  4 
7 Lakshmi 58 F 932265 - - - - - - 89 195 39  5.00 
(L) Capsuloganglionic 
Infarct 
       
4.2  3 
8 Chinnathambi 60 M 931912 - - - - - - 84 181 42  4.30 
(L) Subcortical 
Infarct  
       
3.0  4 
9 Rajammal 80 F 934927 - - - + - - 109 192 43  4.50 
® MCA Massive 
 Infarct 
       
9.8  1 
10 Kasthuri 60 F 943133 - - + - - + 301 209 40  5.23 
(L) Massive Infarct + 
® Frontal Infarct 
 8.1 
Mg  2 
 
S.No. Name 
A 
G 
E 
S 
E 
X 
IP.No 
RISK FACTORS INVESTIGATIONS 
On 
2nd  
Day  
At  
Discharge 
S
m
o
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n
g
 
A
l
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o
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o
l
 
DM HT IHD
O
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E
S
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Y
 
 
Blood 
sugar 
mg 
TC 
Mg 
% 
HDL 
Mg 
% 
 TC 
/ 
HD 
L  
CT Brain Plain 
 HS 
CRP 
Mg / L 
Glasgow 
Outcome 
Scale 
(Score) 
11 Anjalai 61 F 955243 - - - - - - 78 170 45  3.78 
®Sub cortical  
Infarct 
       
2.1  5 
12 Karunanidhi 60 F 941656 - - - - - - 88 168 42  4.00 (L) ACA Infarct 
       
6.2  3 
13 Maideen 55 F 912441 - - - + - - 99 201 46  4.37 (R) Parietal Infarct 
       
4.9  4 
14 Ashokan 44 M 931905 + + + + + + 304 198 38  5.21 (L) MCA Infarct 
       
7.5  3 
15 Chinnaiyan 59 M 925233 + + - - + - 98 210 37  5.67 (L) MCA Infarct 
       
7.6  3 
16 Kanagaraj 57 M 933599 + - - + - - 79 188 36  5.22 (R) MCA Infarct 
       
6.9  3 
17 Thangarajan 75 M 933601 + - - + - - 88 174 40  4.35 (R) MCA Infarct 
       
5.8  3 
18 Kandhan 75 M 933329 - - - - - - 101 196 42  4.66 
(R) 
CapsuloganglionicInfarct 
       
5.4  3 
19 Arokiasamy 45 M 935306 + + - - - - 120 186 45  4.13 
(L)Sub cortical  
Infarct 
       
2.9  4 
20 Vellangani 65 M 935178 + - + + - - 292 211 41  5.14 
(L)MCA Massive 
 Infarct 
       
8.0  2 
21 Chinnakanu 75 M 935338 + - - - - - 113 168 40  4.20 (R) MCA Infarct 
       
6.0  3 
22 Rengasamy 70 M 936125 + - - + - - 98 190 44  4.31 
(R)MCA Massive 
 Infarct 
       
7.4  2 
 
S.No. Name 
A 
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E 
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X 
IP.No 
RISK FACTORS INVESTIGATIONS 
On 
2nd  
Day  
At  
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Blood 
sugar 
mg 
TC 
Mg 
% 
HDL 
Mg 
% 
 TC 
/ 
HD 
L  
CT Brain Plain 
 HS 
CRP 
Mg / L 
Glasgow 
Outcome 
Scale 
(Score) 
23 Natarajan 52 M 938218 + - - - - - 96 160 45  3.50 ® Lacunar Infarct 
       
2.4  5 
24 Taichuddin 67 M 936112 + - + + - + 284 214 37  5.70 
(R)MCA Massive 
 Infarct 
     
10.1  1 
25 Rengasamy 75 M 938714 - - - + - - 94 168 35  4.80 (L)MCA Infarct 
       
6.9  3 
26 Rajagopalan 45 M 934137 + - - - - - 92 180 42  4.29 (L) Parietal Infarct 
       
3.8  4 
27 Ramalingam 56 M 924258 - - - + - - 84 168 44  3.81 (R) MCA Infarct 
       
4.5  4 
28 Palanisamy 60 M 941154 + - - - - - 82 190 43  4.41 (L)MCA Infarct 
       
6.6  3 
29 Raman 70 M 941659 + + - - - - 97 178 39  4.56 (R) MCA Infarct 
       
7.2  3 
30 Marudhamuthu 60 M 941625 + - - + - - 93 156 37  4.22 (L)MCA Infarct 
       
6.8  3 
31 Natesan 69 M 941664 - - - + - - 89 181 38  4.76 (L)MCA Infarct 
       
6.7  3 
32 Subramanian 55 M 941859 + - - - - - 98 162 42  3.86 
(L)Sub cortical  
Infarct 
       
4.4  4 
33 Sadhasivam 70 M 912308 + - + - - - 199 204 38  5.37 (L)MCA Infarct 
       
6.7  3 
34 Ramachandran 43 M 942718 + - - - - - 86 182 46  3.96 
(R)Sub cortical  
Infarct 
       
3.8  4 
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E 
S 
E 
X 
IP.No 
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mg 
TC 
Mg 
% 
HDL 
Mg 
% 
 TC 
/ 
HD 
L  
CT Brain Plain 
 HS 
CRP 
Mg / L 
Glasgow 
Outcome 
Scale 
(Score) 
35 Chinaiyan 75 M 942691 + + + + - - 324 216 37  5.84 
(L)MCA Massive 
 Infarct 
       
8.0  2 
36 Kaliyamoorthi 60 M 945274 - - - + - - 95 196 41  4.78 
(L) 
CapsuloganglionicInfarct 
       
5.5  3 
37 Rajangam 45 M 945275 + - - - - - 88 172 42  4.09 (R) Parietal Infarct 
       
5.6  4 
38 Gopalakrishnan 51 M 946712 - - + - - - 248 188 37  5.08 (L)MCA Infarct 
       
6.1  3 
39 Appadurai 48 M 948367 + - - - - - 89 160 45  3.56 ® Lacunar Infarct 
       
2.4  5 
40 Swamy Nathan 54 M 950133 + - + + + - 314 211 39  5.40 
(L)MCA Massive 
 Infarct 
       
9.6  1 
41 Anthony Samy 64 M 950715 - - - + - - 97 200 41  4.88 
(R) Capsuloganglionic 
Infarct 
       
5.4  3 
42 Savithiri 63 F 950980 - - - + - - 88 210 42  5.00 (R) MCA Infarct 
       
4.8  3 
43 Paavai 70 F 954330 - - + + - - 284 212 40  5.30 (L)MCA Infarct 
       
6.6  3 
44 Marriammal 78 F 951306 - - - + - - 92 200 38  5.26 (L)MCA Infarct 
       
7.1  3 
45 Poongodhai 76 F 954310 - - + + - + 311 210 40  5.25 
(R)MCA Massive 
 Infarct 
       
8.2  2 
46 Murugaiyan 50 F 954335 + - - - - - 89 190 41  4.63 B/L Occipital Infact 
       
4.2  3 
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2nd  
Day  
At  
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TC 
Mg 
% 
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Mg 
% 
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/ 
HD 
L  
CT Brain Plain 
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CRP 
Mg / L 
Glasgow 
Outcome 
Scale 
(Score) 
47 Thangaiyan 55 M 954316 + - - - - - 88 200 45  4.44 
(R)Sub cortical  
Infarct 
       
3.9  5 
48 Gnanasundram 55 M 955286 + - - + - - 86 210 45  4.67 Brain Stem Infarct 
       
5.9  1 
49 Kuppusamy 60 M 955612 + + - + - - 97 200 42  4.76 (L) Cerebellar Infarct 
       
5.1  4 
50 Sivakozhundhu 51 M 947202 + - - + - - 104 164 42  3.90 ® Lacunar Infarct 
       
2.9  5 
51 Rayar 50 M 947181 + + + - - - 401 204 41  4.98 (L)MCA Infarct 
       
6.9  3 
52 Lakshmanan 55 M 954710 + - - + - - 92 168 45  3.73 
(L)Sub cortical  
Infarct 
       
4.9  4 
 
